Table 2.
Early changes in laboratory indices after TCZ
| Indicators | Baseline | Post-treatment | p |
|---|---|---|---|
| CRP mg/L, No MV | n=72 | n=72 | <0.001* |
| Reference range < 6mg/L | 95 (45:150) | 13.5 (5.8:26.0) | |
| CRP mg/L, MV | n=17 | n=17 | 0,014 |
| Reference range <6 mg/L | 89.0 (70.0:191.0) | 35.0 (16.0:105.0) | |
| Lymphocytes/uL, No MV | n=72 | n=72 | 0,036 |
| Reference range 1200-3000/uL | 900 (600:1,200) | 1000 (800:1,400) | |
| Lymphocytes/uL MV | n=17 | n=17 | NSD |
| Reference range 1200-300/uL | 700 (500:800) | 800 (400:1300) | |
| Leukocytes x109/LNoMV | n=71 | n=71 | |
| Reference range 4–9 x109/L | 5,5 (4:7) | 4 (4:5) | |
| NSD | |||
| Leukocytes x 109//L, MV | n=17 | n=17 | 0.02 |
| Reference range 4–19 x 109/L | 5,8 (4:12) | 9,1 (4:11) | |
| Neutrophils x 109//L, No MV | n=71 | n=71 | NSD |
| Reference range 2–7.5 x 109/L | 4,2 (2:6) | 2,8 (2:5) | |
| Neutrophils 109/L MV | n=17 | n=17 | <0.001* |
| Reference range 2–7.5 x 109/L | 3,9 (3:9) | 7,4 (4:11) |
Presented are laboratory indices of patients who were receiving mechanical ventilation (MV) or were not receiving mechanical ventilation (No MV) at initiation of Tocilizumab treatment (baseline) and 1-2 days later. Numbers of patients, medians and interquartile range (IQR) are indicated. NSD-no significant difference.